ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Artificial intelligence-driven cross-endpoint stacked ensemble learning for separate but meta-feature coupled prediction of six human pharmacokinetic endpoints with RDKit molecular representation and applicability domain control on real TDC benchmark data.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Machine learning prediction of human pharmacokinetic (PK) properties usually trains one endpoint at a time, discarding the correlations linking absorption, distribution, metabolism and excretion (ADME) parameters. We developed an artificial-intelligence cross-endpoint stacked ensemble predicting six human PK endpoints within a single modeling framework, coupled through cross-target meta-features, with permutation interpretability and applicability-domain control. The six benchmark sets are independently curated and not compound aligned, so prediction is separate per endpoint, not joint across matched molecules. Six Therapeutics Data Commons (TDC) datasets are as follows: human intestinal absorption (HIA, n = 578), Caco-2 permeability (n = 906), volume of distribution (VDss, n = 1111), plasma protein binding (PPBR, n = 1614), hepatocyte clearance (CL, n = 1020) and half-life (t½, n = 665). Compounds were represented by 34 RDKit descriptors. Per endpoint, four base learners produced leakage-free out-of-fold predictions; pooled across all six endpoints, these formed a 24-dimensional cross-target meta-feature matrix feeding a Ridge or logistic meta-learner. Baselines were a same-endpoint stack and single-task random forest on Bemis-Murcko scaffold splits, with bootstrap intervals and paired tests. The ensemble reached HIA AUROC 0.935 (MCC 0.64), Caco-2 MAE 0.386 (R2 0.60), VDss ρ 0.71, PPBR MAE 9.3%, CL ρ 0.34 and t½ ρ 0.49. It improved on single-task learning for Caco-2 (p = 0.002) and half-life (ρ 0.49 versus 0.36, p = 0.020), tied elsewhere and degraded nothing. The half-life gain exceeded the same-endpoint stack (ρ 0.35), isolating a cross-target effect. Cross-target stacking matches or exceeds single-task learning across six PK endpoints, with the clearest benefit for half-life.
Indexed as
Identifiers
42565845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.